Literature DB >> 20707676

Clostridium difficile and methicillin-resistant Staphylococcus aureus: emerging concepts in vaccine development.

David C Kaslow1, John W Shiver.   

Abstract

Both Clostridium difficile and Staphylococcus aureus asymptomatically colonize a significant percentage of humans, particularly during the first year of life. The epidemiology of both has been and continues to be quite dynamic; presently, we are in the midst of epidemics of infections by C. difficile and S. aureus. These ancient microbes are now armed with more potent virulence factors, which have extended their reach from the hospital into community settings, and from the elderly and debilitated hosts into the younger and otherwise healthy population. This review presents some emerging concepts that will likely shape efforts to develop active and passive immunization interventions in response to the reemergence of these bacterial pathogens.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 20707676     DOI： 10.1146/annurev-med-051109-101544

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN： 0066-4219            Impact factor:   13.739


  10 in total

1.  A Call for Greater Consideration for the Role of Vaccines in National Strategies to Combat Antibiotic-Resistant Bacteria: Recommendations from the National Vaccine Advisory Committee: Approved by the National Vaccine Advisory Committee on June 10, 2015.

Authors: 
Journal:  Public Health Rep       Date:  2016 Jan-Feb       Impact factor: 2.792

Review 2.  Molecular and genetic inflammation networks in major human diseases.

Authors:  Yongzhong Zhao; Christian V Forst; Camil E Sayegh; I-Ming Wang; Xia Yang; Bin Zhang
Journal:  Mol Biosyst       Date:  2016-07-19

3.  NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults.

Authors:  Clint S Schmidt; C Jo White; Ashraf S Ibrahim; Scott G Filler; Yue Fu; Michael R Yeaman; John E Edwards; John P Hennessey
Journal:  Vaccine       Date:  2012-10-22       Impact factor: 3.641

4.  Memory B Cells Encode Neutralizing Antibody Specific for Toxin B from the Clostridium difficile Strains VPI 10463 and NAP1/BI/027 but with Superior Neutralization of VPI 10463 Toxin B.

Authors:  T Scott Devera; Gillian A Lang; Jordi M Lanis; Pragya Rampuria; Casey L Gilmore; Judith A James; Jimmy D Ballard; Mark L Lang
Journal:  Infect Immun       Date:  2015-10-26       Impact factor: 3.441

5.  Targeting RNA polymerase primary σ70 as a therapeutic strategy against methicillin-resistant Staphylococcus aureus by antisense peptide nucleic acid.

Authors:  Hui Bai; Guojun Sang; Yu You; Xiaoyan Xue; Ying Zhou; Zheng Hou; Jingru Meng; Xiaoxing Luo
Journal:  PLoS One       Date:  2012-01-10       Impact factor: 3.240

6.  Expression of Bordetella pertussis Antigens Fused to Different Vectors and Their Effectiveness as Vaccines.

Authors:  Han Xu; Jing Huang; Zhaolu Liu; Xin Li; Kangfeng Wang; Erling Feng; Jun Wu; Li Zhu; Kaihu Yao; Chao Pan; Hengliang Wang
Journal:  Vaccines (Basel)       Date:  2021-05-21

7.  Evaluation of the protective immunity of a novel subunit fusion vaccine in a murine model of systemic MRSA infection.

Authors:  Qian-Fei Zuo; Liu-Yang Yang; Qiang Feng; Dong-Shui Lu; Yan-Dong Dong; Chang-Zhi Cai; Yi Wu; Ying Guo; Jiang Gu; Hao Zeng; Quan-Ming Zou
Journal:  PLoS One       Date:  2013-12-04       Impact factor: 3.240

Review 8.  Applying Convergent Immunity to Innovative Vaccines Targeting Staphylococcus aureus.

Authors:  Michael R Yeaman; Scott G Filler; Clint S Schmidt; Ashraf S Ibrahim; John E Edwards; John P Hennessey
Journal:  Front Immunol       Date:  2014-09-26       Impact factor: 7.561

9.  Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model.

Authors:  Hongyu Qiu; Robyn Cassan; Darrell Johnstone; Xiaobing Han; Antony George Joyee; Monica McQuoid; Andrea Masi; John Merluza; Bryce Hrehorak; Ross Reid; Kieron Kennedy; Bonnie Tighe; Carla Rak; Melanie Leonhardt; Brian Dupas; Laura Saward; Jody D Berry; Cory L Nykiforuk
Journal:  PLoS One       Date:  2016-06-23       Impact factor: 3.240

10.  The Monoclonal Antitoxin Antibodies (Actoxumab-Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with Clostridium difficile Infection.

Authors:  Mária Džunková; Giuseppe D'Auria; Hua Xu; Jun Huang; Yinghua Duan; Andrés Moya; Ciarán P Kelly; Xinhua Chen
Journal:  Front Cell Infect Microbiol       Date:  2016-10-04       Impact factor: 5.293
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.